Brazil Pharma and Healthcare Sector Report 2021-2025

Brazil was one of the hardest-hit nations by the COVID-19 pandemic on a global scale, ranking among the top three countries with the highest number of cases and deaths from the novel coronavirus. Brazil’s pharmaceutical industry, however, managed to adapt to the challenging context created by the pandemic by restructuring product lines and searching for new suppliers. As a result, albeit with higher production costs and lower profitability, it met the rising domestic demand for pharmaceutical products. On the other hand, the pandemic has taken a heavy toll on the country’s universal public health system – SUS – which had been suffering from limited growth of federal funding since January 2018. Moreover, the continued health crisis in the context of a new government austerity stance in 2021 will certainly trigger the debate on much-needed reform of the national health system.​

This report provides a complete and detailed analysis of the healthcare and pharmaceutical sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

The report also includes a separate chapter with 5-year forecasts for the main sectoral and macroeconomic indicators, delivered in the form of both time series and analytical commentaries.

What this report allows you to do:

• Understand the key elements at play in the healthcare and pharmaceutical sector in Brazil
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in Brazil
• Crystallise the forces both driving and restraining this sector in Brazil
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Brazil
• Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels)

See below for a complete table of report contents: